CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (November 2014)

48 slides from CASI Pharmaceuticals's investor presentation, Nov 17, 2014

  1. Slide 1: Presentation

    NASDAQ: CASI www.casipharmaceu6cals.com PRESENTATION November 17, 2014

  2. Slide 2: Forward-Looking Statements

    Forward-­‐Looking Statements This presenta6on contains forward-­‐looking statements within the meaning of the Private Securi6es Li6ga6on Reform Act with respect to the outlook for expecta6ons for future financial or business performance, strategies, expecta6ons and goals. Forward-­‐looking statements

  3. Slide 3: Company Overview

    Company Overview • We are a U.S. based, NASDAQ-­‐listed company and plan to become an integrated biopharmaceu6cal company with significant market share in China, while establishing partnerships for global development and commercializa6on • Our business model is to leverage our exper6se and resources

  4. Slide 4: Inflection Points in 2015

    Inflec6on Points in 2015 • ENMD-­‐2076: We plan to ini6ate an advanced-­‐stage clinical trial for ENMD-­‐2076 in fibrolamellar carcinoma (FLC) • FDA IND allowance received • Orphan drug designa6on received for hepatocellular carcinoma (HCC), which includes FLC • Strong science and clinical and regulat

  5. Slide 5: Pipeline: Proprietary Drug Candidates For Global Market

    Pipeline Proprietary Drug Candidates For Global Market Slide 5

  6. Slide 6: Pipeline: In-licensed Products For Greater China Market

    Pipeline In-­‐licensed Products For Greater China Market Slide 6

  7. Slide 7: ENMD-2076: Orally Active Multiple Kinase Inhibitor

    ENMD-­‐2076 A Proprietary Orally Ac>ve Mul>ple Kinase Inhibitor with An>angiogenic and An>prolifera>ve Mechanism of Ac>on Orally available protein Kinase Inhibitor Unique combina6on of mul6ple targets Address cancer cell prolifera6on, angiogenesis Slide 7

  8. Slide 8: Induces Cell Cycle Arrest at G2/M

    ENMD-­‐2076 Induces Cell Cycle Arrest at G2/M (4N) Consistent With Inhibi>on of Aurora A 5 Days 20 µM 1 µM ENMD-2076 24 hours HCT-116 No drug 2N 4N 8N Cell Numbers (HCT116) 5 µM ENMD-2076 20 µM Control 1 µM MK-0457 20 µM 1 µM MK-0457 2N 4N 8N Slide 8

  9. Slide 9: ENMD-2076 Inhibits FGF-Driven Angiogenesis in Matrigel In Vivo

    ENMD-­‐2076 Inhibits FGF-­‐Driven Angiogenesis in Matrigel In Vivo Inhibits Formation of Blood Vessels Regresses Newly Formed Blood Vessels - bFGF –bFGF d13 Control + bFGF +bFGF d7 Control 25 mg/kg +bFGF d13 PO BID 50 mg/kg 150 mg/kg PO BID bid d7- d13 Slide 9

  10. Slide 10: ENMD-2076 Pre-Clinical Summary

    ENMD-­‐2076 Pre-­‐Clinical Summary First in class, poten>ally a novel targeted therapy for mul>ple cancer indica>ons • Orally ac6ve, mul6-­‐kinase inhibitor that inhibits Aurora A and several important receptor tyrosine kinases to avoid development of resistance • Dose-­‐dependent ac6vity in ectopic

  11. Slide 11: ENMD-2076 Completed Clinical Trials

    ENMD-­‐2076 Completed Clinical Trials ENMD-­‐2076 Phase I Phase II 2076-­‐CL-­‐001: Open-­‐Label, 2076-­‐CL-­‐002: Study of 2076-­‐CL-­‐003: Study of 2076-­‐CL-­‐004: Study of Dose-­‐Escala6on, Safety, and ENMD-­‐2076 in Pa6ents with ENMD-­‐2076 in Pa6ents with ENMD-­‐2076 in Pa6ents with PK Study o

  12. Slide 12: ENMD-2076 Phase I Data: Good Safety Profile and Antitumor Activity

    ENMD-­‐2076 Phase I Data Demonstrated Good Safety Profile and Promising Preliminary An>tumor Ac>vity in Mul>ple Types of Solid Tumors Recommended dose: ‒ 160 mg/m2/d 60% 60 mg/m2/d 50% 80 mg/m2/d Overall response rate 40% 120 mg/m2/d ‒ Par6al Response: 3% 200 mg/m2/d ‒ Stable Disease: 85% (30% 30% 16

  13. Slide 13: ENMD-2076 Current Ongoing Trials

    ENMD-­‐2076 Current Ongoing Trials ENMD-­‐2076 Phase II Phase II Study of ENMD-­‐2076 in Phase II Study of Oral Phase II Study of Oral Phase II Study of Oral Pa6ents with Previously Treated ENMD-­‐2076 Administrated to ENMD-­‐2076 Administrated to ENMD-­‐2076 Administrated to Locally Advanced and Pa

  14. Slide 14: ENMD-2076 Clinical Summary

    ENMD-­‐2076 Clinical Summary A drug candidate with good safety and poten>al efficacy in niche indica>ons • Phase I – Ac6vity shown in a variety of solid and hematological cancer pa6ents – Responses in pla6num refractory/resistant ovarian cancer – Par6al Response in FLC-­‐HCC pa6ent – Par6al Response i

  15. Slide 15: ENMD-2076: Potential Targeted Therapy for TNBC

    ENMD-­‐2076 A Poten>al Targeted Therapy for Triple-­‐Nega>ve Breast Cancer (TNBC) • Robust single agent an6-­‐TNBC ac6vi6es were demonstrated in vitro and in vivo including mdr human TNBC xenograp models • p53-­‐based genomic profiling was iden6fied as a candidate for predic6ve biomarker for pa6ent se

  16. Slide 16: ENMD-2076: Potential Targeted Therapy for Soft Tissue Sarcoma

    ENMD-­‐2076 A Poten>al Targeted Therapy for SoX Tissue Sarcoma (STS) • Inhibi6on of Aurora kinases abrogates tumor development and progression of sop 6ssue sarcoma in animal model as published in literature • Inhibi6on of angiogenesis delayed the progression of the disease as demonstrated in clinica

  17. Slide 17: ENMD-2076: Potential Targeted Therapy for Clear Cell Ovarian Cancer

    ENMD-­‐2076 A Poten>al Targeted Therapy for Clear Cell Ovarian Cancer • Aurora A is open over expressed in ovarian cancer cells • VEGF is frequently expressed in ovarian clear cell carcinoma • Demonstrated single agent ac6vity in tumor models of human ovarian cancer Pre-­‐clinical • Synergis6c effect

  18. Slide 18: ENMD-2076: Potential to Treat Fibrolamellar Carcinoma

    ENMD-­‐2076 A Poten>al to treat Fibrolamellar Carcinoma (FLC) • Fibrolamellar carcinoma (FLC) is a rare malignant neoplasm of the liver, represen6ng 0.6% to 8.6% of all hepatocellular carcinomas.* • FLC has a dis6nct clinical and histological prognosis, and generally occurs in young individuals. It

  19. Slide 19: Scientific Rationale: Role of Aurora A in FLC

    Scien6fic Ra6onale Role of Aurora A in Fibrolamellar Carcinoma (FLC) A Recurrent DNAJB1-­‐PRKACA Chimeric Transcript is Detected in FLC* • The chimeric transcript is expressed in FLC but not in adjacent liver • The chimeric RNA is predicted to code for a protein containing the amino-­‐terminal domain

  20. Slide 20: Scientific Rationale: Role of VEGF and FGFR in FLC

    Scien6fic Ra6onale Role of VEGF and FGFR in Fibrolamellar Carcinoma (FLC) • VEGF is one of the main inducers of liver tumor angiogenesis. Increased levels of VEGF have been observed in HCC. • Hepatoma cells are believed to possess a prolifera6on mechanism regulated by an autocrine mechanism, a paracr

  21. Slide 21: Clinical Rationale: Evidence of Efficacy in FLC Patient

    Clinical Ra6onale Evidence of ENMD-­‐2076 Efficacy in Fibrolamellar Carcinoma (FLC) Pa>ent FLC Par;al Response Observed in Phase I Trial of ENMD-­‐2076 April 2007 Pa6ent received diagnosis of FLC Oct 2007 Pa6ent received TACE therapy with Doxorubicin/Cispla6n Jan 2008 Pa6ent received TACE therapy with

  22. Slide 22: ENMD-2076: Potential to be First Drug to Treat FLC

    ENMD-­‐2076 A Poten>al to be First Drug to Treat Fibrolamellar Carcinoma (FLC) • ENMD-­‐2076: targe6ng VEGF, FGFR, and Aurora A • Preclinical animal data demonstrated ac6vity in hepatocellular carcinoma (HCC) models • Clinical evidence supports ra6onale for further clinical trials • FDA: granted Orp

  23. Slide 23: ZEVALIN Launch in Hong Kong in 2015

    ZEVALIN® Launch in Hong Kong in 2015 A Dual-­‐Commercializa6on Approach: • A CD20-­‐directed, isotope labeled McAb, approved and currently marketed by partner (Spectrum) for follicular non-­‐Hodgkins lymphoma (NHL), with ongoing Phase III trial in diffuse large B cell lymphoma (DLBCL) • Launch in Hon

  24. Slide 24: MARQIBO File for Marketing Approval in Greater China in 2015

    MARQIBO® File for Marke>ng Approval in greater China in 2015 A Dual-­‐Commercializa6on Approach: • Liposome encapsulated formula6on of vincris6ne, approved and currently marketed by partner (Spectrum) for second line (Ph-­‐) adult acute lymphocy6c leukemia (ALL), with ongoing Phase III trial in untr

  25. Slide 25: Captisol-Enabled Melphalan

    Cap6sol-­‐Enabled™ Melphalan A Dual-­‐Development Approach: • Cap6sol-­‐Enabled formula6on of an alkyla6ng chemotherapy agent for mul6ple myeloma, indicated for condi6oning agent prior to stem cell transplant • NDA filing expected by partner/Spectrum in 2014 " •File Import Drug Applica6ons aper partn

  26. Slide 26: 2ME2 (2-Methoxyestradiol)

    2ME2 (2-­‐Methoxyestradiol) An Orally Ac>ve Compound that has An>-­‐Prolifera>ve, An>-­‐ Angiogenic and An>-­‐Inflammatory Proper>es •Significant efficacy in animal models of mul6ple cancers and autoimmune disorders, including rheumatoid arthri6s and mul6ple sclerosis •Addi6onal preclinical studies ongo

  27. Slide 27: Experienced Board and Management Determined to Deliver Results

    Experienced Board and Management Determined to Deliver Results BOARD OF DIRECTORS Dr. Wei-­‐Wu He, Chairman Chairman & CEO, Origene Technologies, Inc. Dr. Tak W. Mak, Chief Scien>fic Advisor Director, Campbell Family Research Ins6tute/Princess Margaret Hospital; University Professor, University of To

  28. Slide 28: 2013-2014 A Year of Accomplishments

    2013-­‐2014 A Year of Accomplishments Clinical Achievements ! Ini6ated Phase II clinical trial for ENMD-­‐2076 in ovarian clear cell carcinoma at Princess Margaret Hospital ! CFDA approves applica6on to start a China trial for ENMD-­‐2076 in triple-­‐nega6ve breast cancer ! Filed clinical trial appl

  29. Slide 29: 2014-2015 Milestones

    2014-­‐2015 Milestones ! Complete crossover bioavailability formula6on study for ENMD-­‐2076 ! File clinical trial applica6on with the CFDA for ENMD-­‐2076 in ovarian clear cell carcinoma ! June 2014 ASCO poster for sop 6ssue sarcoma trial ! June 2014 ASCO poster for ovarian clear cell carcinoma tri

  30. Slide 30: Investment Highlights

    Investment Highlights • Undervalued, with significant defined milestones in 2015 and beyond. Near-­‐term inflec6on points include: – Ini6a6ng advanced clinical trial for ENMD-­‐2076 in fibrolamellar hepatocellular carcinoma (FLC), with poten6al to be first drug to address FLC – Launching commercial ac6vi

  31. Slide 31: NASDAQ: CASI www.casipharmaceuticals.com

    NASDAQ: CASI www.casipharmaceu6cals.com

  32. Slide 32: Appendices

    Appendices Pharmaceuticals

  33. Slide 33: Antitumor Activity of ENMD-2076 in Orthotopic Breast Cancer Model

    ENMD-­‐2076 An>tumor Ac>vity of ENMD-­‐2076 Alone or in Combina>on with CDDP in an Orthotopic MDA-­‐MB-­‐231 Human Triple Nega>ve Breast Cancer Model Group Protocol-1 Protocol-2 Protocol-3 Protocol-1 Protocol-2 Protocol-3 (Mice) Day 34- 49 Day 50- 64 Day 65-82 G1 No ENMD-2076 Off study 2000 treatmen

  34. Slide 34: ENMD-2076 Effects in HT-29 Colon Cancer Xenograft Tumors

    ENMD-­‐2076 Effects in HT-­‐29 Colon Cancer XenograX Tumors PET CT showed significant decreases in 18FDC uptake aper treatment, associated with a marked reduc6on in prolifera6on as assessed by Ki-­‐67 Slide 34

  35. Slide 35: Antitumor Activity of ENMD-2076 with Paclitaxel in Ovarian Model

    ENMD-­‐2076 An>tumor Ac>vity of ENMD-­‐2076 Along or in Combina>on with Paclitaxel in a TOV-­‐21G Ectopic Human Ovarian Carcinoma Model 100 Incidence Tumor Regression/Cohort (%) 90 • 9 mice/cohort 8/9 • 46 treatment days 80 • MTD regimen of Paclitaxel • Combination is tolerable 70 60 50 4/9 4/9 40 3

  36. Slide 36: Antitumor Activity of ENMD-2076 in HCC Xenograft Models

    ENMD-­‐2076 An>tumor Ac>vity of ENMD-­‐2076 in Three Different Human Hepatocellular Carcinoma (HCC) XenograX Model Slide 36

  37. Slide 37: Antitumor Activity of ENMD-2076 Against Breast Cancer Cell Lines

    ENMD-­‐2076 An>tumor Ac>vity of ENMD-­‐2076 Against Breast Cancer Cell Lines In Vitro ENMD-­‐2076 demonstrated more robust ac6vity against cell lines of the Triple-­‐ Nega6ve Breast Cancer subtype compared to the luminal and HER2-­‐ amplified subtypes Slide 37

  38. Slide 38: Predictive Biomarkers of TNBC Sensitivity to ENMD-2076

    ENMD-­‐2076 Predic>ve Biomarkers of Triple-­‐Nega>ve Breast Cancer (TNBC) Sensi>vity to ENMD-­‐2076 TNBC cell lines with a p53 muta6on and/or p53 over expression showing more sensi6ve to the cytotoxic and pro-­‐apopto6c effects of ENMD-­‐2076 Slide 38

  39. Slide 39: Phase I Results Waterfall Plot of RECIST Measurements

    -50% -40% -30% -20% -10% 0% 10% 20% 30% 40% 50% 60% colorectal Slide 39 colorectal ovarian pancreatic colorectal cervical ovarian rectal colorectal colorectal trachea colon colon ovarian melanoma renal cell ovarian cervical gastric colorectal ovarian rectal pancreatic breast colorectal colon ovarian

  40. Slide 40: CT Images from a Soft Tissue Sarcoma Patient

    ENMD-­‐2076 CT Images from a SoX Tissue Sarcoma Pa>ent Baseline CT before treatment CT post 4 cycle of treatment Slide 40

  41. Slide 41: 2ME2 Effects on Mouse Model of Multiple Sclerosis

    2ME2 (2-­‐Methoxyestradiol) Effects of 2ME2 on Auto-­‐immune Mouse Model of Mul>ple Sclerosis (MS) • Suppress development of autoimmune disorders in mouse experimental model of mul6ple sclerosis (MS) • Inhibit in vitro lymphocyte ac6va6on, cytokine produc6on, and prolifera6on in a dose-­‐dependent fa

  42. Slide 42: 2ME2 Significant In Vivo Antitumor Activities

    2ME2 (2-­‐Methoxyestradiol) Significant In Vivo An>tumor Ac>vi>es Demonstrated, Especially in Combina>on with Standard of Care An6tumor Ac6vity of 2ME2 in Combina6on with XRT on PC3 Tumor Growth 1000 n = 5 mice/group 800 Control T-­‐C (days) to 2ME2 75 mg/kg/d po x 5 reach 200 mm3 Radia6on 2 Gy 0 Tum

  43. Slide 43: 2ME2 Efficacy in Animal Models for Arthritis

    2ME2 (2-­‐Methoxyestradiol) Significant Single-­‐agent In Vivo efficacy Demonstrated in Experimental Animal Models for Arthri>s Adop6ve Transferred Adjuvant Arthri6s Mean Arthri6c Scores 6 Vehicle 2ME2 3 mg/kg/d d0-­‐21 2ME2 30 mg/kg/d d5-­‐19 4 Arthri6s Score 2 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 D

  44. Slide 44: Rationale for CASI North America/China Development Strategy

    Ra6onale for CASI North America/China Development Strategy • North America and the West are genera6ng most of the innova6on and drug discoveries • The FDA’s guidance has great impact on the CFDA’s views and decisions • Drug development costs, par6cularly clinical development costs in the U.S., are p

  45. Slide 45: China Pharmaceutical Market: A Significant, Unprecedented Opportunity

    China Pharmaceu6cal Market A Significant, Unprecedented Opportunity • China is the fastest growing pharmaceu6cal market in the world • The percentage of healthcare spending in GDP is low among developed countries, while growing at fast pace in China • The pharmaceu6cal market will con6nue to grow wit

  46. Slide 46: China Pharmaceutical Market Second Largest by 2016

    China Pharmaceu6cal Market Second Largest by 2016 China is projected to be the second largest pharmaceu6cal market in the world by 2016 Within the pharmaceu6cal market, oncology is the largest and fastest growing Slide 46

  47. Slide 47: China Pharmaceutical Market Fastest Growing

    China Pharmaceu6cal Market Fastest Growing Slide 47 Appendix -­‐ 4

  48. Slide 48: China Cancer Growth Opportunity to Address Significant Unmet Medical Needs

    China Cancer Growth Opportunity to Address Significant Unmet Medical Needs Tumor incidence and death are expected to grow rapidly worldwide • Cancer incidence is expected to reach 1.7 million in the U.S. and 3.4 million in China in 2015 • Cancer incidence is expected to increase to 2.1 million in the

CASI Pharmaceuticals — Investor Presentation (November 2014) on 6ix